introduced the bipartisan Drug Origin Transparency Act, legislation to give the Food and Drug Administration (FDA), health care providers, and purchasers better visibility into where prescription drugs and their key ingredients are actually made
Require the Food and Drug Administration, health care providers, and purchasers to have better visibility into where prescription drugs and their key ingredients are made.
Occurrences
Evidence
unverified · Source version 20790 · locator unknown
Matsui, Doris O. ... 06/26/2025 | Introduced in House ... Related bill ... S.1784 ... MAPS Act.
unverified · Source version 20791 · locator unknown
This Act may be cited as the “Mapping America’s Pharmaceutical Supply Act” or the “MAPS Act.” ... to improve coordination of Federal efforts to identify and mitigate health and national security risks through maintaining a list of essential medicines, conducting a risk assessment of essential medicine supply chains, and creating a monitoring system to map essential medicine supply chains using data analytics.
unverified · Source version 20792 · locator unknown
SEC. 1067. MAPPING AMERICA’S PHARMACEUTICAL SUPPLY. ... map, or otherwise visualize, the supply chains, from manufacturing of key starting materials through manufacturing of finished dosage forms and distribution, of drugs and biological products, including the active ingredients of those drugs and biological products ... [and] the location of establishments ... involved in the production of drugs and biological products ... [and] the location of establishments ... involved in the production of the key starting materials and excipients needed to produce each drug and biological product.
unverified · Source version 65031 · locator unknown
Last Action Date Listed April 16, 2026 Action Ms. Matsui (for herself, Mr. Crenshaw, Ms. Schrier, and Mrs. Hinson) introduced the following bill; which was referred to the Committee on Energy and Commerce
unverified · Source version 65033 · locator unknown
Mapping America’s Pharmaceutical Supply The Senate bill contained a provision (sec. 1083) that would require the Secretary of Health and Human Services
Assessments
Matsui materially advanced the promise by introducing the MAPS Act in the House on June 26, 2025, and the bill text directly targets supply-chain mapping and visibility into drug ingredients and manufacturing locations. A later Senate amendment pursued the same concept, showing a serious legislative effort. But the provided record does not show enactment or that the promised requirement was actually imposed on the FDA, providers, and purchasers. Under the stated rule, a serious attempt that did not deliver the outcome is scored as never with effort credit.
Rep. Doris Matsui materially advanced the promise by introducing H.R. 4191, the MAPS Act, in the 119th Congress. The bill directly matches the promise: it would create a monitoring and mapping system for pharmaceutical supply chains, including key starting materials, active ingredients, finished drugs, and manufacturing locations, improving visibility for federal authorities and related health-system stakeholders. Additional Senate amendment text shows the concept continued to be pursued. However, the provided record does not show enactment into law or that FDA, providers, and purchasers were actually required to have this visibility. Because there was a serious legislative effort but no demonstrated delivery of the promised outcome, this should be scored as not fulfilled with effort credit.